Paget’s disease Treatment

Paget’s Disease Treatment Market Outlook

As of 2023, the global Paget's disease treatment market is valued at approximately USD 1.7 billion, with a projected compound annual growth rate (CAGR) of 5.6% from 2025 to 2035. This growth is primarily driven by the increasing prevalence of Paget's disease among aging populations and advancements in treatment approaches that enhance patient outcomes. Additionally, the rising awareness regarding the disease and its treatment options, coupled with an improved healthcare infrastructure, is propelling market growth. Furthermore, ongoing research and clinical trials aimed at finding more effective therapies are expected to contribute significantly to market expansion. Consequently, the market is poised for substantial growth as it adapts to the evolving needs of patients and healthcare providers.

Growth Factor of the Market

The Paget's disease treatment market is experiencing positive momentum due to several growth factors that are shaping the landscape of this therapeutic segment. One of the foremost drivers is the increasing incidence of Paget's disease, particularly in older adults, which is leading to a heightened demand for effective treatment solutions. Additionally, ongoing advancements in pharmacological research, particularly in the development of bisphosphonates and other targeted therapies, have significantly improved treatment efficacy. Another critical factor is the growing investments in healthcare infrastructure, especially in emerging markets, which are facilitating better access to medications and healthcare services for patients suffering from this chronic condition. Moreover, the rising awareness among healthcare professionals and patients about Paget’s disease has led to earlier diagnosis and treatment interventions, further enhancing market growth. The trend towards personalized medicine, which tailors treatment based on individual patient profiles, is also gaining traction, presenting new opportunities for treatment innovations tailored to the needs of those affected by Paget's disease.

Key Highlights of the Market

• The global Paget's disease treatment market is expected to grow at a CAGR of 5.6% from 2025 to 2035.
• Bisphosphonates remain the leading treatment option owing to their effectiveness in managing the disease.
• North America holds a significant share of the market, driven by high healthcare spending and advanced treatment options.
• There is an increasing trend towards combination therapies, which enhance treatment outcomes for patients.
• Emerging economies in the Asia Pacific region are witnessing rapid growth in demand for Paget's disease treatments due to improved healthcare access.

By Treatment Type

Bisphosphonates:

Bisphosphonates are the cornerstone of Paget's disease treatment, effectively reducing bone resorption and managing symptoms associated with the disease. These medications work by inhibiting osteoclast activity, leading to a decrease in bone turnover and alleviating pain. The availability of various bisphosphonates, such as alendronate and risedronate, has provided physicians with options to tailor treatment based on patient needs. The preferred mode of administration is typically oral, which enhances compliance among patients. Research supporting the long-term efficacy and safety of bisphosphonates continues to fuel their widespread use, making them a dominant force in the treatment landscape for Paget’s disease.

Calcitonin:

Calcitonin, a hormone that regulates calcium levels in the body, serves as an alternative treatment option for Paget's disease. It is particularly beneficial for patients who cannot tolerate bisphosphonates or for whom these medications are contraindicated. Calcitonin works by inhibiting osteoclast activity, thus reducing bone resorption. It is often used in combination with other therapies to maximize treatment effectiveness. However, its use has declined over the years due to the availability of more potent medications such as bisphosphonates. Nevertheless, calcitonin remains a viable option, especially for patients experiencing acute pain or those requiring a quick therapeutic response.

NSAIDs:

Nonsteroidal anti-inflammatory drugs (NSAIDs) are primarily employed to manage pain associated with Paget’s disease, although they do not address the underlying bone metabolism issues. These medications, which include ibuprofen and naproxen, are widely accessible and can provide effective relief from pain and inflammation that patients experience. While NSAIDs are not a definitive treatment for the disease itself, they play a crucial role in symptom management, particularly for patients with mild to moderate discomfort. The ease of use and accessibility of NSAIDs contribute to their sustained presence in the treatment regimen for Paget’s disease.

Corticosteroids:

Corticosteroids may be prescribed in specific cases to manage severe pain or complications arising from Paget's disease. These anti-inflammatory agents act quickly to reduce pain and swelling, providing relief for patients experiencing acute symptoms. However, their long-term use is limited due to potential side effects, including osteoporosis, which can exacerbate the very condition being treated. As a result, corticosteroids are generally considered a short-term solution rather than a primary treatment option. Their application is typically reserved for patients who do not respond adequately to other pain management strategies, highlighting the importance of personalized treatment approaches in managing Paget's disease.

Surgical Intervention:

Surgical intervention may be indicated for patients with complications arising from Paget's disease, such as fractures or severe deformities that impair mobility. Surgical options may include osteotomy or joint replacement procedures, aimed at correcting structural abnormalities and restoring function. Although surgery is not the primary treatment for Paget's disease itself, it can significantly improve the quality of life for patients with advanced complications. The decision to pursue surgical intervention is based on a thorough assessment of the patient's overall health, disease progression, and response to medical therapies, emphasizing the need for a multidisciplinary approach to treatment.

By Route of Administration

Oral:

The oral route of administration is the most commonly employed method for delivering Paget's disease treatments, particularly bisphosphonates and NSAIDs. This approach offers significant advantages in terms of patient compliance, as medications can be taken conveniently at home. Oral formulations provide an effective means for long-term management of Paget's disease, allowing patients to maintain their treatment regimens without the need for frequent healthcare visits. Additionally, the oral route minimizes the discomfort associated with injections, further enhancing patient adherence to prescribed therapies.

Intravenous:

Intravenous (IV) administration is used in specific cases where rapid therapeutic effects are required or when patients cannot tolerate oral medications. Medications such as zoledronic acid, a potent bisphosphonate, are administered intravenously to achieve quick and effective management of Paget's disease symptoms. The intravenous route is particularly beneficial for patients with severe pain or those at risk of complications from oral administration due to gastrointestinal issues. While IV treatments may require healthcare professional supervision, their ability to deliver immediate results makes them a valuable option in the treatment landscape.

Intramuscular:

Intramuscular (IM) injections are less commonly utilized in the treatment of Paget’s disease but may be recommended for specific medications, such as calcitonin, in cases where other routes are not feasible. The IM route provides a means of delivering medication directly into the muscle, allowing for faster absorption compared to oral forms. This method is particularly useful for patients who require immediate relief from symptoms but may not have good absorption through the gastrointestinal tract. However, intramuscular administration generally requires healthcare professionals to administer the treatment, which can pose logistical challenges for routine management.

Subcutaneous:

Subcutaneous (SC) administration involves delivering medication into the fatty tissue just below the skin, which allows for gradual absorption into the bloodstream. This route is sometimes utilized for medications like calcitonin, providing an alternative for patients who may experience gastrointestinal side effects from oral medications. Subcutaneous injection can be performed by patients themselves once they receive proper training, promoting adherence to the treatment regimen. The SC route is advantageous for patients who prefer autonomy in managing their health, ensuring they can obtain necessary relief from Paget’s disease symptoms without frequent medical visits.

Topical:

Topical treatments for Paget’s disease are not mainstream; however, they may be recommended for localized pain management. Topical nonsteroidal anti-inflammatory drugs (NSAIDs) can be applied directly to painful areas, allowing for targeted relief without systemic side effects. While this method is more common for managing pain from other conditions, it offers an alternative approach for patients seeking to manage localized discomfort associated with Paget's disease. The effectiveness of topical treatments depends on the individual patient’s response, and they are often used in conjunction with systemic therapies for comprehensive management of the disease.

By Distribution Channel

Hospitals:

Hospitals serve as a primary distribution channel for Paget's disease treatments, particularly for patients requiring immediate and comprehensive care. In a hospital setting, patients have access to a range of treatment options, including intravenous medications and surgical interventions, under the supervision of healthcare professionals. Hospitals also play a critical role in patient education and follow-up care, ensuring that treatment regimens are adhered to and that potential complications are managed effectively. Additionally, hospitals often conduct clinical trials that contribute to the development of new therapies, further enhancing the treatment landscape for Paget’s disease.

Clinics:

Clinics offer a vital distribution channel for Paget's disease treatments, providing an accessible setting for outpatient care. Many patients receive ongoing management of their condition in clinic settings, where they can obtain prescriptions for oral medications and receive guidance on lifestyle modifications. Clinics are often staffed by specialists, including endocrinologists and orthopedic surgeons, who can provide tailored treatment plans for individual patients. The convenience of clinics allows for regular monitoring of disease progression, making them an integral part of the healthcare continuum for those with Paget’s disease.

Retail Pharmacies:

Retail pharmacies represent a significant distribution channel for Paget's disease treatments, particularly for oral medications such as bisphosphonates and NSAIDs. With their widespread availability and convenience, retail pharmacies enable patients to obtain prescriptions quickly and easily. Additionally, many pharmacies offer consultation services, providing patients with valuable information on medication use, potential side effects, and interactions. The presence of retail pharmacies in communities fosters greater access to treatments, ensuring that patients can manage their condition effectively without significant barriers.

E-commerce:

The rise of e-commerce has transformed the distribution landscape for Paget's disease treatments, allowing patients to purchase medications online from the comfort of their homes. This shift has been particularly beneficial for individuals living in remote areas with limited access to healthcare facilities. E-commerce platforms often provide competitive pricing and a wide selection of medications, making it easier for patients to find the treatments they need. However, it is essential for consumers to ensure that they are purchasing medications from reputable sources to guarantee product quality and safety. The trend toward online pharmacies is expected to continue growing, driven by increasing consumer comfort with digital healthcare solutions.

Others:

Other distribution channels for Paget's disease treatments include specialty pharmacies and telehealth services, which have emerged as important avenues for patient access to medications. Specialty pharmacies focus on providing medications for complex conditions and often offer additional support services, including patient education and adherence programs. Telehealth services, particularly in the wake of the COVID-19 pandemic, have enabled patients to consult with healthcare providers remotely and receive prescriptions for necessary treatments without needing to visit a physical clinic. These alternative distribution channels are expanding patient access to Paget's disease treatments, catering to the diverse needs of individuals managing their condition.

By Patient Type

Adults:

Adults represent a significant patient demographic in the Paget's disease treatment market, as the condition typically manifests in individuals aged 40 and older. Treatment approaches for adults are often tailored to address the unique challenges faced by this age group, including comorbidities and variations in disease severity. Management strategies may include a combination of pharmacological treatments, lifestyle modifications, and regular monitoring to ensure optimal outcomes. The focus on adult patients underscores the need for healthcare providers to adopt a comprehensive approach to managing Paget’s disease, emphasizing the importance of individualized treatment plans that consider the patient's overall health status.

Geriatric Population:

The geriatric population is particularly vulnerable to Paget's disease, necessitating specialized treatment strategies that account for age-related factors. This demographic often presents with additional health concerns, such as osteoporosis, which can complicate treatment decisions. As such, healthcare providers must carefully evaluate the risks and benefits of various treatment options for older adults, ensuring that therapies are both effective and safe. Emphasis on pain management and maintaining mobility is critical in this patient group, highlighting the importance of a multidisciplinary approach that includes physical therapy and supportive care. The growing elderly population is expected to drive demand for targeted treatments, making geriatric care a focal point in the Paget's disease treatment landscape.

By Region

The North American region dominates the Paget's disease treatment market, accounting for approximately 40% of the global market share as of 2023. Factors contributing to this dominance include high healthcare spending, well-established healthcare infrastructure, and widespread awareness of Paget's disease among healthcare professionals and patients alike. Furthermore, North America is home to several leading pharmaceutical companies actively involved in research and development of innovative treatment options. The region is expected to maintain a robust CAGR of 6% over the forecast period, driven by continuous advancements in treatment modalities and increasing patient population seeking effective management strategies.

In Europe, the Paget's disease treatment market is also substantial, representing about 30% of the global market. The European market is characterized by a high prevalence of Paget's disease, particularly in countries with aging populations such as the United Kingdom and Germany. The region is seeing a shift towards more personalized treatment approaches, with an increasing emphasis on patient-centered care. As healthcare policies evolve to enhance access to treatments, the European market is projected to grow at a CAGR of 5.2% during the forecast period. Emerging economies in Asia Pacific are anticipated to witness the fastest growth, attributed to improving healthcare access and rising awareness regarding Paget's disease management.

Opportunities

The Paget's disease treatment market presents numerous opportunities for stakeholders looking to enhance their position in this evolving landscape. One significant opportunity lies in the development of novel therapeutics that target the underlying pathophysiology of Paget's disease more effectively than current treatment options. Research into biologics and gene therapies is gaining traction, with the potential to revolutionize the treatment paradigm for patients. Additionally, there is an increased focus on combination therapies that harness the strengths of multiple treatment modalities to improve patient outcomes, creating opportunities for pharmaceutical companies to innovate and differentiate their products. The integration of digital health technologies, such as telehealth and mobile health applications, offers another avenue for enhancing patient engagement and adherence to treatment regimens, ultimately improving overall quality of life.

Furthermore, stakeholders in the market can explore opportunities in emerging markets, where rising incomes and improving healthcare infrastructure are paving the way for increased access to treatments. Companies that can successfully navigate these new markets by forming strategic partnerships or local collaborations stand to benefit significantly from the growing demand for Paget's disease therapies. As awareness of Paget's disease continues to expand among healthcare providers and patients, there is a promising avenue for education and advocacy efforts to enhance recognition and early intervention. In this context, organizations focusing on building awareness campaigns and supporting research initiatives may find themselves well-positioned to seize the opportunities presented by the growing Paget's disease treatment market.

Threats

Despite the promising growth prospects in the Paget's disease treatment market, several threats could impede progress and pose challenges for stakeholders. One of the primary concerns is the rising cost of healthcare and medications, which may limit access to essential treatments for patients. High prices can lead to non-adherence, particularly in populations with limited financial resources or inadequate insurance coverage, ultimately impacting patient outcomes and satisfaction. Additionally, the evolving regulatory landscape presents a challenge for pharmaceutical companies, as stringent compliance requirements may delay the approval of new therapies and limit market entry for innovative treatments. The increasing focus on value-based care may also necessitate changes in treatment approaches, compelling healthcare providers to justify the cost-effectiveness of therapies, which could strain the market dynamics.

Moreover, competition from alternative therapies and treatment modalities can threaten the market's growth. The emergence of non-pharmacological interventions, such as physical therapy and lifestyle modifications, may influence treatment preferences, particularly among patients seeking holistic approaches to manage their condition. This trend could lead to a shift in healthcare resources and investments away from traditional pharmaceuticals. Finally, the limited awareness and understanding of Paget's disease among certain patient populations may result in delayed diagnosis and treatment, further complicating the management of the disease. Addressing these threats will require collaboration among stakeholders, including healthcare providers, pharmaceutical companies, and advocacy groups, to ensure that patients receive timely and effective care.

Competitor Outlook

• Novartis AG
• Bristol-Myers Squibb
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Pfizer Inc.
• Roche Holding AG
• Sanofi S.A.
• Johnson & Johnson
• Eli Lilly and Company
• AbbVie Inc.
• Regeneron Pharmaceuticals Inc.
• Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Takeda Pharmaceutical Company Limited

The competitive landscape of the Paget's disease treatment market is characterized by a diverse array of players, ranging from established pharmaceutical giants to emerging biotech firms focused on innovative therapies. The market is primarily dominated by a few key players, such as Novartis AG and Amgen Inc., which offer a comprehensive portfolio of treatment options tailored for Paget's disease. These companies invest heavily in research and development to create novel therapies and improve existing products, ensuring they remain competitive in a rapidly evolving market. Additionally, the presence of generic manufacturers further intensifies competition, providing patients with more affordable treatment alternatives, which can influence prescribing practices and market dynamics.

Moreover, strategic partnerships and collaborations among companies are increasingly common as organizations seek to leverage each other's strengths and expertise. This trend is evident in the growing number of mergers and acquisitions within the pharmaceutical industry, as companies aim to expand their market presence and enhance their product offerings. For instance, collaborations between biotechnology firms and larger pharmaceutical companies can accelerate the development of innovative therapies, allowing for more rapid market entry. The focus on patient-centric approaches is also driving competition, with companies striving to create value-added services and personalized treatment regimens that cater to the unique needs of individuals living with Paget's disease.

Several major companies are making significant strides in the Paget's disease treatment market, including Pfizer Inc. and Sanofi S.A. Pfizer is known for its strong pipeline of biologics and small molecules aimed at managing bone disorders, ensuring it remains a key player in the market. Additionally, Sanofi's commitment to research and development has led to advancements in treatment options, positioning it favorably among healthcare providers. Other notable companies, such as Eli Lilly and Company, focus on developing targeted therapies that address the specific needs of Paget's disease patients while prioritizing safety and efficacy. As the market continues to grow, the competitive landscape will evolve, and companies must remain agile and responsive to changes in patient demand and regulatory requirements.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Mylan N.V.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Sanofi S.A.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Roche Holding AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Johnson & Johnson
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Merck & Co., Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Bristol-Myers Squibb
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Eli Lilly and Company
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Hoffmann-La Roche Ltd.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Regeneron Pharmaceuticals Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Teva Pharmaceutical Industries Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Takeda Pharmaceutical Company Limited
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Paget’s disease Treatment Market, By Patient Type
    • 6.1.1 Adults
    • 6.1.2 Geriatric Population
  • 6.2 Paget’s disease Treatment Market, By Treatment Type
    • 6.2.1 Bisphosphonates
    • 6.2.2 Calcitonin
    • 6.2.3 NSAIDs
    • 6.2.4 Corticosteroids
    • 6.2.5 Surgical Intervention
  • 6.3 Paget’s disease Treatment Market, By Distribution Channel
    • 6.3.1 Hospitals
    • 6.3.2 Clinics
    • 6.3.3 Retail Pharmacies
    • 6.3.4 E-commerce
    • 6.3.5 Others
  • 6.4 Paget’s disease Treatment Market, By Route of Administration
    • 6.4.1 Oral
    • 6.4.2 Intravenous
    • 6.4.3 Intramuscular
    • 6.4.4 Subcutaneous
    • 6.4.5 Topical

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Paget’s disease Treatment Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Paget’s disease Treatment market is categorized based on

By Treatment Type

• Bisphosphonates
• Calcitonin
• NSAIDs
• Corticosteroids
• Surgical Intervention

By Route of Administration

• Oral
• Intravenous
• Intramuscular
• Subcutaneous
• Topical

By Distribution Channel

• Hospitals
• Clinics
• Retail Pharmacies
• E-commerce
• Others

By Patient Type

• Adults
• Geriatric Population

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Novartis AG
• Bristol-Myers Squibb
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Pfizer Inc.
• Roche Holding AG
• Sanofi S.A.
• Johnson & Johnson
• Eli Lilly and Company
• AbbVie Inc.
• Regeneron Pharmaceuticals Inc.
• Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Takeda Pharmaceutical Company Limited